China Biologic Products Holdings, Inc. at its annual general meeting held on July 2, 2018 shareholders of the company did not approve the re-election of Mr. Albert (Wai Keung) Yeung as a Class III director. As a result, Mr. Yeung has not been re-elected as a director of the company. The company also announced that its Board elected Mr. David Hui Li as the new chairman of the Board, effective July 1, 2018.

Mr. David (Xiaoying) Gao, who served for more than six years as the Board's chairman, remains a director on the Board. In addition, Mr. Gao has stepped down from the position of the Chief Executive Officer of the company. The Board is actively seeking a new Chief Executive Officer and has appointed Mr. Zhijun Tong as the acting Chief Executive Officer in the interim.

Mr. David Hui Li has been a member of Board since November 4, 2013. Mr. David Hui Li was an executive director and a managing director at Warburg Pincus Asia LLC ("Warburg Pincus") from February 2002 to January 2016. Mr. Zhijun Tong has been a member of Board since April 20, 2012.

He has served on many boards of directors, including as chairman of the board. The companies in which Mr. Tong has held board or senior management positions include Spain Qifa Corporation Ltd., Hong Kong Tong's Group, Sunstone (Qingdao) Plant Oil Co. Ltd., Sunstone (Qingdao) Food Co.

Ltd., Shengda (Zhangjiakou) Pharmaceutical Co. Ltd., Shengda (Qianxi) Chinese Medicine Cultivation Co. Ltd. and Spain International Haisitan Group.